AstraZeneca signs its first deal with Kangtai Bio to supply potential COVID-19 vaccine in China


News provided by

Comserve Inc.

Aug 10, 2020, 05:30 EST


Bronx, United States, Aug 10, 2020, 05:30 /Comserve / -- The British drug-maker, AstraZeneca signed an exclusive deal with Beijing based Shenzhen Kangtai Biological Products Co., Ltd to manufacture a potential COVID-19 vaccine in mainland China.

Image placeholder

Beijing, August 07,2020:  The British drug-maker, AstraZeneca signed an exclusive deal with Beijing based Shenzhen Kangtai Biological Products Co., Ltd to manufacture a potential COVID-19 vaccine in mainland China.

Shenzhen Kangtai is considered as one of the leading Chinese vaccine manufacturers. Under the agreement, Shenzhen Kangtai will ensure that it has an annual manufacturing capacity of at least 100 million doses by the end of this year and at least 200 million doses at the end of the next year 2021, of the experimental shot AZD1222 which AstraZeneca has co-developed with Oxford University researchers.

Till date, AstraZeneca has signed vaccine manufacturing agreements with the United States, South Korea, Brazil and Britain. These deals are to produce more than 2 billion vaccine doses. Multiple Chinese companies are also developing their own COVID-19 vaccine candidates. These includes Sinovac Biotech, CanSino Biologics and Sinopharm. On June 15, Sinovac Biotech announced positive results from Phase 1 and 2 of Corona vaccine trial. Similarly, CanSino Biologics also reported positive test results from Phase 2 trial of the vaccine, Ad5-nCOV.

Other collaborations between Chinese and international vaccine-makers include Germany’s BioNTech’s partnership with China’s Fosun and Inovio Pharma’s pact with Beijing based Advaccine Biotechnology. Apart from China, other COVID-19 vaccine programs that seem to be at the forefront are US-based companies Pfizer, Novavax and Moderna. Novavax reported positive test results from Stage 1 and 2 trials of the vaccine NVX-C0V2373 while Moderna conducted its Phase 3 human trial of its vaccine on 30,000 volunteers this week. Apart from the above three companies, the US Government is also funding AstraZeneca, GlaxoSmithKline Johnson & Johnson, Merck, and Sanofi. This project aims to provide over 300 million doses of COVID vaccine distributed in the U.S. by early 2021.

While the pace with which vaccines are being produced and evaluated is incredible, many scientists have voiced fear about the effectiveness of these vaccines.

About AstraZeneca

AstraZeneca was founded in the year 1999. It is a British-Swedish pharmaceutical company headquartered in Cambridge, England.

About Kangtai Bio

Kangtai Biological Products Co., Ltd. is a listed enterprise that specializes in manufacturing biological products including vaccines. It is Headquartered in Shenzhen.

COMSERVE empowers communicators by offering modern digital PR solutions and distribution services to identify and engage with customers, opinion leaders, bloggers and other relevant audience.


For more information, please contact:

Anna R .Moser

Comserve Inc.
Email: info@comserveonline.com
Tel: 859-228-3939

Related Links
https://www.comserveonline.com/



Also from this source


Global Drones Market To Expand With Increasing Military Expenditure and Increasing Application Of Drones By A CAGR of 19.90% Throughout 2019-2027

The global drones market is anticipated to record a CAGR of 19.90% during the forecast period, i.e.


Telefónica Deutschland Picks Tech Mahindra For Network And Services Operations

Telefónica Deutschland, one of the largest telephone operators and mobile network suppliers in the